CNS Pharmaceuticals Files 8-K: Security Holder Rights & Exhibits

Ticker: CNSP · Form: 8-K · Filed: 2025-02-21T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing, corporate-actions

TL;DR

CNS Pharmaceuticals filed an 8-K on Feb 19, 2025, updating security holder rights and filing exhibits.

AI Summary

On February 19, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The filing also includes financial statements and exhibits, with the company's principal executive offices located at 2100 West Loop South, Suite 900, Houston, Texas.

Why It Matters

This 8-K filing provides crucial updates on changes affecting CNS Pharmaceuticals' security holders and includes important financial and exhibit information for investors.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting material modifications and other events, not indicating immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific material modifications to the rights of security holders are detailed in this 8-K filing?

The filing indicates 'Material Modifications to Rights of Security Holders' as an item, but the specific details of these modifications are not provided in the provided text excerpt.

What are the 'Other Events' reported by CNS Pharmaceuticals, Inc. on February 19, 2025?

The filing lists 'Other Events' as a reported item, but the specific nature of these events is not detailed in the provided excerpt.

Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?

The principal executive offices of CNS Pharmaceuticals, Inc. are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

What is the state of incorporation for CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What is the SEC File Number for CNS Pharmaceuticals, Inc.?

The SEC File Number for CNS Pharmaceuticals, Inc. is 001-39126.

From the Filing

0001683168-25-001174.txt : 20250221 0001683168-25-001174.hdr.sgml : 20250221 20250221170008 ACCESSION NUMBER: 0001683168-25-001174 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250219 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250221 DATE AS OF CHANGE: 20250221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25652874 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm CURRENT REPORT 8-K false 0001729427 0001729427 2025-02-19 2025-02-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 19, 2025 ___________________________   CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ___________________________   Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (800) 946-9185   Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbols(s) Name of each exchange on which registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC               Item 3.03. Material Modifications of Rights of Security Holders.   At the CNS Pharmaceuticals, Inc. (the “Company”) special meeting of stockholders held on November 26, 2024, the stockholders of the Company approved a proposal granting the Company’s board of director

View on Read The Filing